{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dose+Finding+Study",
    "query": {
      "condition": "Dose Finding Study"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 856,
    "total_pages": 86,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dose+Finding+Study&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-27T11:39:52.944Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04789655",
      "title": "Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia, Myeloid"
      ],
      "interventions": [
        {
          "name": "CC-96191",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2021-06-16",
      "completion_date": "2025-04-14",
      "has_results": false,
      "last_update_posted_date": "2025-05-31",
      "last_synced_at": "2026-06-27T11:39:52.944Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Jacksonville, Florida • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04789655"
    },
    {
      "nct_id": "NCT01565655",
      "title": "A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "peficitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 289,
      "start_date": "2012-06-19",
      "completion_date": "2013-12-02",
      "has_results": false,
      "last_update_posted_date": "2025-05-21",
      "last_synced_at": "2026-06-27T11:39:52.944Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Palm Desert, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01565655"
    },
    {
      "nct_id": "NCT01106508",
      "title": "A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Recurrent or Refractory Medulloblastoma",
        "Locally Advanced or Metastatic Basal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "LEQ506",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2010-10",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2020-12-17",
      "last_synced_at": "2026-06-27T11:39:52.944Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • New York, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01106508"
    },
    {
      "nct_id": "NCT01480050",
      "title": "Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "3'-deoxy-3'-[18F]fluorothymidine",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "Mibefradil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 28,
      "start_date": "2012-05-31",
      "completion_date": "2017-06-01",
      "has_results": false,
      "last_update_posted_date": "2019-05-22",
      "last_synced_at": "2026-06-27T11:39:52.944Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01480050"
    },
    {
      "nct_id": "NCT00226278",
      "title": "Safety Study of ORG 34517 for Major Depression With Psychotic Features",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Major Depressive Disorder",
        "Psychotic Disorders"
      ],
      "interventions": [
        {
          "name": "ORG 34517",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 25,
      "start_date": "2004-09",
      "completion_date": "2005-11",
      "has_results": false,
      "last_update_posted_date": "2008-03-31",
      "last_synced_at": "2026-06-27T11:39:52.944Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00226278"
    },
    {
      "nct_id": "NCT01607658",
      "title": "Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Female Orgasmic Disorder"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Low dose TBS-2",
          "type": "DRUG"
        },
        {
          "name": "Medium dose TBS-2",
          "type": "DRUG"
        },
        {
          "name": "High dose TBS-2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acerus Pharmaceuticals Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 253,
      "start_date": "2012-05",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2018-08-13",
      "last_synced_at": "2026-06-27T11:39:52.944Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01607658"
    },
    {
      "nct_id": "NCT06827236",
      "title": "A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Breast Cancer",
        "Unresectable Breast Carcinoma",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "BNT323",
          "type": "DRUG"
        },
        {
          "name": "BNT327",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 380,
      "start_date": "2025-04-23",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-06-27T11:39:52.944Z",
      "location_count": 20,
      "location_summary": "Beverly Hills, California • Newport Beach, California • Port Saint Lucie, Florida + 15 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06827236"
    },
    {
      "nct_id": "NCT01894516",
      "title": "Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "GLPG0634",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lakefront Biotherapeutics NV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 287,
      "start_date": "2013-10-08",
      "completion_date": "2015-05-29",
      "has_results": true,
      "last_update_posted_date": "2020-12-16",
      "last_synced_at": "2026-06-27T11:39:52.944Z",
      "location_count": 21,
      "location_summary": "Gilbert, Arizona • Mesa, Arizona • Phoenix, Arizona + 18 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Hemet",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01894516"
    },
    {
      "nct_id": "NCT02003092",
      "title": "RX-5902 Treatment of Subjects With Triple Negative Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "RX-5902",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rexahn Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2013-08",
      "completion_date": "2019-11",
      "has_results": false,
      "last_update_posted_date": "2020-01-06",
      "last_synced_at": "2026-06-27T11:39:52.944Z",
      "location_count": 8,
      "location_summary": "Tucson, Arizona • Aurora, Colorado • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02003092"
    },
    {
      "nct_id": "NCT00044733",
      "title": "Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "Mylotarg (gemtuzumab ozogamicin) Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "0 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2000-03",
      "completion_date": "2004-09",
      "has_results": false,
      "last_update_posted_date": "2006-05-18",
      "last_synced_at": "2026-06-27T11:39:52.944Z",
      "location_count": 13,
      "location_summary": "Little Rock, Arkansas • Hartford, Connecticut • Jacksonville, Florida + 10 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Olathe",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00044733"
    }
  ]
}